This company profile is not publicly available
Acquired by Actavis (now Allergan) in 2014 for US$28 billion.
|Forest Laboratories Inc||USA||website|
| Allergan plc
owns 100% of Forest Laboratories Inc
|Forest Laboratories Inc|
In 2009, the U.S. Department of Justice accused Forest Labs of marketing Lexapro for unapproved uses, failing to disclose negative results from clinical trials and paying kickbacks to doctors who prescribed the drug. In 2010, this company's US subsidiary, Forest Pharmaceuticals Inc., agreed to pay more than $313 million to settle the charges over Lexapro and two other drugs, Levothroid and Celexa. Lexapro has been linked to serious birth defects. More lawsuits are pending.
[Source 2012][More on Irresponsible marketing]
Nearly 2,000 patients benefitted from a $300 million settlement announced in 2017 by Benicar manufacturer Daiichi Sankyo and co-promoter Forest Laboratories. The settlement is to compensate the patients for severe gastrointestinal side effects they say they developed after taking Benicar and related high-blood pressure medications.
[Source 2017][More on Irresponsible marketing]
This company received a score of 0/100 in the Newsweek Green Rankings 2014, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights.
[Source 2014][More on Sustainability Reporting]
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B-.
[Source 2018][More on Climate Change]
This company received a SAM Rank of 65/100 in the Pharmaceuticals category of the 2018 SAM Corporate Sustainability Assessment. The index is based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
[Source 2018][More on Sustainability Reporting]
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of C.
[Source 2018][More on Human Rights]
|Company Structure||Wholly-owned subsidiary|
|Revenue||US$4.2 billion in 2010|
|# Employees||5,200 in 2010|
|Address||New York, USA|